 |
|
|
| |
Second-line treatment with novel PPAR agonists in patients with primary biliary cholangitis:
Real-world experience from a European tertiary care center
|
| |
| |
EASL 2026 May26-30 Barcelona
Miriam M. Düll1, 2, Jonas Schmid1, 2, Marcel Vetter1, 2, Markus F. Neurath1, 2, Andreas E. Kremer3, Peter Dietrich1, 2, 4
1 Department of Medicine 1, University Hospital and Friedrich-Alexander-University Erlangen-Nürnberg,
Erlangen, Germany, 2 Deutsches Zentrum Immuntherapie DZI, Erlangen, Erlangen, Germany,
3 Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich,
Switzerland, 4 Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander-University Erlangen-
Nürnberg, Erlangen, Germany
|
| |
|
|
|
|
|
